Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Since influenza vaccines are normally administered every year because of the frequent change
 in their antigenic composition, the safety and immunogenicity profile of adjuvanted influenza
 vaccine need to be re-evaluated after repeated vaccine administration. In this study,
 subjects previously vaccinated with Fluarix or the influenza adjuvanted vaccine, will receive
 a booster dose with the 2006-2007 season's formulations of either Fluarix or the adjuvanted
 vaccine.
Inclusion Criteria:

 -  The subjects must be healthy elderly >/= 67 years and previously vaccinated with
 Fluarix or the adjuvanted vaccine.

 Exclusion Criteria:

 -  Subjects will be excluded if they take/have taken chronically high doses of
 immunosuppressants or other immunemodifying drugs within six months before
 vaccination, or immunoglobulins or blood products within three months before
 vaccination, or any investigational product within 30 days before vaccination, have a
 history of influenza infection since previous vaccination, or if subjects have acute
 or chronic clinically significant disease or an immunosuppressive/deficient condition,
 or have contra-indications to influenza vaccination